CCM
ABMD

CAAS Capital Management’s Abiomed Inc ABMD Stock Holding History

CAAS Capital Management’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-7,400
Closed -$1.07M – 504
2020
Q1 		$1.07M Buy
+7,400
New +$1.23M 0.11% 130

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

CAAS Capital Management's ABMD Position: Q2 2021 in Review

CAAS Capital Management sold out of Abiomed Inc (ABMD) in Q2 2021, closing a stake of 14,481 shares — an estimated $4.62M sold.

CAAS Capital Management first reported a position in ABMD in Q1 2021 and held it in 1 quarter. The position peaked at $4.62M in Q1 2021. 474 funds tracked by Wall St. Rank hold ABMD as of Q2 2021.

  • CAAS Capital Management reported no remaining Abiomed Inc position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 14,481 Abiomed Inc shares in Q2 2021, an estimated $4.62M.
  • CAAS Capital Management first reported a position in Abiomed Inc in Q1 2021 and held it in 1 quarter.
  • CAAS Capital Management's Abiomed Inc position peaked at $4.62M in Q1 2021.
  • 474 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.